Eloxx Pharmaceuticals, Inc.
ELOX
$0.00
-$0.13-98.39%
OTC PK
| 03/31/2026 | 03/31/2025 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.14M | 712.00K | 1.80M | 2.00M | 3.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.80M | 1.22M | 4.14M | 5.48M | 6.03M |
| Operating Income | -3.80M | -1.22M | -4.14M | -5.48M | -6.03M |
| Income Before Tax | -3.75M | -1.71M | -4.34M | -6.23M | -6.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.75M | -1.71M | -4.34M | -6.23M | -6.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.75M | -1.71M | -4.34M | -6.23M | -6.32M |
| EBIT | -3.80M | -1.22M | -4.14M | -5.48M | -6.03M |
| EBITDA | -- | -1.21M | -4.13M | -5.47M | -6.02M |
| EPS Basic | -0.08 | -0.45 | -1.96 | -2.88 | -2.92 |
| Normalized Basic EPS | -0.05 | -0.28 | -1.23 | -1.68 | -1.82 |
| EPS Diluted | -0.08 | -0.45 | -1.96 | -2.88 | -2.92 |
| Normalized Diluted EPS | -0.05 | -0.28 | -1.23 | -1.68 | -1.82 |
| Average Basic Shares Outstanding | 48.21M | 3.81M | 2.21M | 2.17M | 2.17M |
| Average Diluted Shares Outstanding | 48.21M | 3.81M | 2.21M | 2.17M | 2.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |